| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
|
Clark, Richard E.
|
|
|
5 |
4 |
p. 1102-1109
|
article
|
| 2 |
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
|
Löwenberg, Bob
|
|
|
5 |
4 |
p. 1110-1121
|
article
|
| 3 |
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
|
Grunwald, Michael R.
|
|
|
5 |
4 |
p. 975-983
|
article
|
| 4 |
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
|
Lyman, Gary H.
|
|
|
5 |
4 |
p. 927-974
|
article
|
| 5 |
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial
|
Ohmachi, Ken
|
|
|
5 |
4 |
p. 984-993
|
article
|
| 6 |
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
|
Hunter, Anthony M.
|
|
|
5 |
4 |
p. 1017-1028
|
article
|
| 7 |
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry
|
Bassand, Jean-Pierre
|
|
|
5 |
4 |
p. 1081-1091
|
article
|
| 8 |
Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML
|
Mareschal, Sylvain
|
|
|
5 |
4 |
p. 1003-1016
|
article
|
| 9 |
Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients
|
Mohyuddin, Ghulam Rehman
|
|
|
5 |
4 |
p. 1097-1101
|
article
|
| 10 |
Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients
|
Yan, Melissa
|
|
|
5 |
4 |
p. 1050-1058
|
article
|
| 11 |
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
|
Patel, Kishan K.
|
|
|
5 |
4 |
p. 994-1002
|
article
|
| 12 |
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN
|
Voorhees, Peter M.
|
|
|
5 |
4 |
p. 1092-1096
|
article
|
| 13 |
Editorial Board
|
|
|
|
5 |
4 |
p. i
|
article
|
| 14 |
In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice
|
Li, Chang
|
|
|
5 |
4 |
p. 1122-1135
|
article
|
| 15 |
Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation
|
Davis, Zachary
|
|
|
5 |
4 |
p. 1069-1080
|
article
|
| 16 |
Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.
|
|
|
|
5 |
4 |
p. 1136
|
article
|
| 17 |
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature
|
Alimam, Samah
|
|
|
5 |
4 |
p. 1059-1068
|
article
|
| 18 |
Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion
|
Rius, Bibiana
|
|
|
5 |
4 |
p. 1037-1049
|
article
|
| 19 |
Prognostic restaging after treatment initiation in patients with AL amyloidosis
|
Abdallah, Nadine
|
|
|
5 |
4 |
p. 1029-1036
|
article
|
Journal description